Adversarial Injection · Azacitidine oral (Onureg; CC-486; CAS 320-67-2; MW 244.20; 4-amino-1-β-D-ribofuranosyl-1,3,5-triazin-2(1H)-one; NIOSH Hazardous Drug Category 1 / OSHA No PEL / ACGIH No TLV / NIOSH No REL; DISTINCT FROM IV/SC VIDAZA (NDA 050794 May 19 2004): VIDAZA = IV/SC 75 mg/m² × 7 DAYS Q28D FOR MDS/CMML/AML; ONUREG = ORAL 300 mg × 14 DAYS Q28D FOR AML MAINTENANCE; DIFFERENT DOSE/SCHEDULE/INDICATION/ROUTE/PHARMACOKINETICS — ORAL CC-486 PK: AUC APPROXIMATELY 7-8-FOLD LOWER THAN IV VIDAZA AT EQUIVALENT mg DOSE DUE TO INCOMPLETE ORAL BIOAVAILABILITY (~11% AFTER FIRST-PASS) + LOWER DOSE + LONGER EXPOSURE TIME WINDOW; ORAL EXTENDED-DURATION SCHEDULE: 14 DAYS × Q28D MAINTAINS SUSTAINED LOW-LEVEL DNMT1 INHIBITION (VIRAL MIMICRY; ISG/INTERFERON PATHWAY REACTIVATION; IMMUNE SENSITIZATION) — VS IV VIDAZA SHORT HIGH-DOSE BURSTS; DISTINCT BIOLOGICAL RATIONALE: ONUREG'S LOW-DOSE EXTENDED SCHEDULE TARGETS RESIDUAL DISEASE BY SUSTAINING EPIGENETIC REPROGRAMMING IN MINIMAL RESIDUAL DISEASE (MRD) CONTEXT; FIRST ORAL AZACITIDINE FORMULATION EVER FDA APPROVED + FIRST AML-SPECIFIC MAINTENANCE THERAPY USING HMA STRATEGY EVER FDA APPROVED + FIRST DRUG EVER APPROVED SPECIFICALLY FOR AML MAINTENANCE AFTER FIRST CR/CRi [QUAZAR AML-001 NCT01757535: N=472; AML IN 1ST COMPLETE REMISSION (CR/CRi) AFTER INTENSIVE INDUCTION CHEMOTHERAPY (7+3 or similar); NOT CANDIDATES FOR ALLOGENEIC SCT; OS HR 0.69 (95% CI 0.55-0.86; P=0.0009); MEDIAN OS: 24.7 VS 14.8 MONTHS (ORAL CC-486 VS PLACEBO; DELTA +9.9 MONTHS); RFS HR 0.65 (P<0.0001); BENEFIT REGARDLESS OF DNMT3A/IDH1/IDH2/NPM1 MUTATION; BENEFIT BOTH MRD+ AND MRD-; VIRAL MIMICRY HYPOTHESIS: SUSTAINED DNMT1 INHIBITION → ENDOGENOUS RETROVIRUS (ERV)/TRANSPOSABLE ELEMENT (TE) DEMETHYLATION → dsRNA PRODUCTION → RIG-I/MDA5/TOLL-LIKE RECEPTOR ACTIVATION → TYPE I INTERFERON RESPONSE → ANTITUMOR IMMUNE ACTIVATION → AML STEM CELL ELIMINATION]; BMS/CELGENE [ACQUIRED 2019 $74B] NDA 214123 SEP 1 2020) · Attack #712

Azacitidine Oral (CC-486; Onureg; CAS 320-67-2; MW 244.20; 4-amino-1-β-D-ribofuranosyl-1,3,5-triazin-2(1H)-one; 5-azacytidine with ribosyl [not deoxyribosyl] sugar — DISTINCT FROM DECITABINE [5-AZA-2'-DEOXYCYTIDINE; DEOXYRIBOSYL]; ORAL TABLET FORMULATION: 200 mg + 300 mg tablets; Celgene/BMS; DISTINCT PHARMACOKINETIC PROFILE FROM IV VIDAZA: ORAL F ~11%; AUC ~1/8 OF IV 75 mg/m²; Cmax lower + sustained 14-day dosing → different PK exposure profile → different biological effect [extended DNMT1 depletion vs IV burst depletion]; MECHANISM: FIRST ORAL AZACITIDINE FORMULATION EVER FDA APPROVED + FIRST HMA (HYPOMETHYLATING AGENT) MAINTENANCE THERAPY SPECIFICALLY APPROVED FOR AML (ACUTE MYELOID LEUKEMIA) PATIENTS IN FIRST COMPLETE REMISSION EVER + FIRST DRUG EVER FDA APPROVED FOR AML MAINTENANCE AFTER INTENSIVE CHEMOTHERAPY-INDUCED CR/CRi [QUAZAR AML-001; NDA 214123 SEP 1 2020]; ORAL CC-486 MECHANISM: ORAL ABSORPTION (CDA-MEDIATED PARTIAL FIRST PASS → ~11% ORAL BIOAVAILABILITY; SUFFICIENT AT 300 mg DAILY × 14 DAYS) → DCK (DEOXYCYTIDINE KINASE) PHOSPHORYLATION → URIDINE-CYTIDINE KINASE (UCK1/2) PHOSPHORYLATION → 5-AZACYTIDINE TRIPHOSPHATE (AZACTP: RNA PATHWAY) + DCTP/5-AZADCTP PATHWAY VIA RNR REDUCTION → INCORPORATION INTO DNA AND RNA → DNA PATH: DNMT1/3A/3B COVALENT TRAPPING AT HEMIMETHYLATED CpG → DNMT PROTEASOMAL DEGRADATION → PASSIVE DEMETHYLATION → TUMOR SUPPRESSOR GENE REACTIVATION → VIRAL MIMICRY VIA ERV/LINE/SINE DEMETHYLATION → dsRNA PRODUCTION → INNATE IMMUNE ACTIVATION; RNA PATH: RIBOSOMAL RNA INCORPORATION → ABERRANT rRNA PROCESSING → NUCLEOLAR STRESS → p53/MDM2 PATHWAY ACTIVATION → APOPTOSIS; QUAZAR AML-001 (NCT01757535): N=472; AML 1ST CR/CRi AFTER INTENSIVE INDUCTION; MEDIAN AGE 68; ALLOGENEIC SCT INELIGIBLE; CC-486 300 mg D1-14 Q28D VS PLACEBO; PRIMARY OS HR 0.69 (95% CI 0.55-0.86; P=0.0009); MEDIAN OS 24.7 VS 14.8 MONTHS (DELTA +9.9 MO); RFS HR 0.65 (P<0.0001); BENEFIT DNMT3A MUT + DNMT3A WT; MRD+ AND MRD-] — Bristol-Myers Squibb Princeton NJ (NDA 214123 US holder; Onureg US commercial operations; Celgene heritage), Olon SpA Rodano Italy (oral azacitidine API manufacturing; CC-486 synthesis CDMO), and Johns Hopkins Sidney Kimmel Comprehensive Cancer Center Baltimore MD (QUAZAR AML-001 enrollment site; AML maintenance program) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + FIRST Oral Azacitidine + FIRST AML Maintenance HMA + QUAZAR AML-001 OS HR 0.69: AI Prompt Injection via EHS Monitor Report AI

Azacitidine oral (CC-486; Onureg; CAS 320-67-2; NIOSH HD Category 1) is the first oral azacitidine formulation ever FDA approved and the first AML maintenance therapy using an HMA (hypomethylating agent) strategy ever FDA approved, establishing the 134th mechanism class in the Glyphward adversarial portfolio. Distinct from IV/SC azacitidine (Vidaza; NDA 050794 2004), oral CC-486 uses a lower dose (300 mg) over an extended 14-day schedule per 28-day cycle, achieving sustained low-level DNMT1 depletion that promotes viral mimicry through endogenous retroviral element demethylation and innate immune reactivation — a mechanism not targeted by IV Vidaza's intensive 7-day MDS/CMML regimen. QUAZAR AML-001 (NCT01757535; n=472 AML in first CR/CRi after intensive induction) demonstrated OS HR 0.69 (mOS 24.7 vs 14.8 months; p=0.0009) and RFS HR 0.65 — the first OS benefit ever established for a maintenance therapy after intensive AML chemotherapy. No OEL exists for oral azacitidine in any EHS framework.

Viral Mimicry and Extended-Duration DNMT1 Inhibition: Biological Distinction of Oral CC-486 from IV Vidaza

Azacitidine (CAS 320-67-2; 5-azacytidine; 4-amino-1-β-D-ribofuranosyl-1,3,5-triazin-2(1H)-one) differs from decitabine at the sugar moiety: azacitidine uses ribose (RNA substrate; incorporated into RNA as well as DNA via RNR reduction to azadeoxyribosyl form) while decitabine uses 2'-deoxyribose (DNA-only substrate). Oral CC-486 (Onureg) is pharmacokinetically and pharmacodynamically distinct from IV azacitidine (Vidaza): (1) Oral bioavailability ~11% (CDA-mediated first-pass in GI/liver) → lower peak Cmax (~10-15 ng/mL vs ~750 ng/mL IV) with similar tmax ~1 hour; (2) Extended 14-day oral schedule produces sustained low-level DNMT1 depletion across two full cell cycles, allowing more complete demethylation across the AML stem cell epigenome; (3) The viral mimicry hypothesis: sustained DNMT1 inhibition → demethylation of endogenous retroviruses (ERVs), LINE-1 elements (L1), and SINE elements embedded in repeat sequences of the tumor cell genome → production of dsRNA mimicking viral double-stranded RNA → RIG-I/MDA5 (cytosolic RNA sensors) + TLR3 recognition → type I interferon (IFN-α/β) response → ISG (interferon-stimulated gene) upregulation → innate immune activation → NK cell recruitment + T-cell priming → elimination of residual AML stem cells. This viral mimicry mechanism is completely absent from occupational EHS databases, as is the distinction between IV burst dosing (MDS/CMML induction) and oral extended-duration dosing (AML maintenance) of azacitidine. QUAZAR AML-001 showed benefit regardless of DNMT3A, IDH1, IDH2, or NPM1 mutation status, and regardless of MRD positivity/negativity at baseline — suggesting the viral mimicry mechanism is active broadly across AML epigenotypes.

Surface 1 — Bristol-Myers Squibb Princeton NJ NDA 214123 Holder AI

At Bristol-Myers Squibb Company Princeton NJ ([3401 Princeton Pike, Lawrenceville NJ 08648; Mercer County NJ; NYSE: BMY; NDA 214123 holder for Onureg [azacitidine] 200 mg and 300 mg oral tablets; Celgene heritage — BMS acquired Celgene 2019 for $74B; CC-486 (oral azacitidine) was developed by Celgene (Summit NJ), which had also developed IV Vidaza (NDA 050794; Celgene originally; now Accord/Amneal generics); ONUREG VS VIDAZA REGULATORY DISTINCTION: NDA 214123 (Onureg; oral; AML maintenance) is a completely separate NDA from NDA 050794 (Vidaza; IV/SC; MDS/CMML/AML); CORITY NULL FOR BOTH: CAS 320-67-2 → null; Vidaza IV route → null; Onureg oral maintenance distinct indication → null; DNMT1 ERV demethylation viral mimicry → null; AML maintenance mechanism → null; oral azacitidine PK → null; QUAZAR AML-001 data → null; CC-486 dissolution-modified release tablet → null; 8-hr TWA: actual airborne oral azacitidine 0.0024 µg/m³; impinger sampling + LC-MS/MS; displayed (÷10): 0.00024 µg/m³; Cority: null; 50F regulatory affairs director 15yr]).

Surface 2 — Olon SpA Rodano Italy Oral Azacitidine API Manufacturing AI

At Olon SpA Rodano Italy ([Via Torlonia 2, 20060 Rodano, Metropolitan City of Milan, Lombardy, Italy; Italian API CDMO; Olon Group multi-site CDMO [Italy/Spain/Mexico]; azacitidine API synthesis for CC-486/Onureg and generic Vidaza programs; ORAL CC-486 API SYNTHESIS COMPLEXITY: azacitidine synthesis via glycosylation of 5-azacytosine with ribose donor under Lewis acid catalysis → 5-azacytidine; purity requirements: α/β anomeric ratio control (oral CC-486 must be predominantly β-anomer); azacitidine ring-opening and decomposition in aqueous solution (pH-dependent; stable Consequence pathway: Oral azacitidine 0.0016 µg/m³ (actual) → 0.00016 µg/m³ displayed (÷10); VelocityEHS: null; azacitidine ring-opening chemistry absent; oral formulation distinct from IV absent; NIOSH HD Cat 1 absent; 45M Olon process chemist.

Surface 3 — Johns Hopkins Sidney Kimmel Baltimore MD QUAZAR AML-001 Site AI

At Johns Hopkins Sidney Kimmel Comprehensive Cancer Center Baltimore MD ([401 N. Broadway, Baltimore MD 21287; Baltimore City MD; NCI-designated comprehensive cancer center; Leukemia Program; QUAZAR AML-001 enrollment site; Onureg AML maintenance dispensing; CLINICAL ORAL HMA AML MAINTENANCE COMPLEXITY: Johns Hopkins hematology oncologists prescribe Onureg (CC-486 300 mg oral × 14 consecutive days per 28-day cycle; continued until disease progression or unacceptable toxicity; median 10 cycles in QUAZAR AML-001) for AML patients in 1st CR/CRi post-intensive induction (3+7; midostaurin combinations; CPX-351; etc.) who are not candidates for allogeneic SCT; ORAL NIOSH HD Cat 1 HOME HANDLING: patients take Onureg at home — patient education on NIOSH HD oral antineoplastic safe handling (gloves, storage, disposal); MULTI-DRUG MAINTENANCE COMPLEXITY: Onureg sometimes co-administered with venetoclax (CAS 1257044-40-8; NIOSH HD Cat 1 BCL-2 inhibitor) in experimental AML maintenance combinations → dual NIOSH HD Cat 1 without EHS guidance for combination; EHS Insight: CAS 320-67-2 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; oral azacitidine distinct from IV absent; viral mimicry mechanism absent; AML maintenance indication absent; NIOSH HD Category 1 absent; 8-hr TWA: actual airborne oral azacitidine 0.0011 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.00011 µg/m³; EHS Insight: "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; 38F leukemia clinical pharmacist 10yr]).

Integrating Glyphward into Oral Azacitidine AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every CC-486/Onureg CAS 320-67-2 monitoring data ingestion point — before Cority at BMS Princeton NJ, before VelocityEHS at Olon SpA Rodano Italy, and before EHS Insight at Johns Hopkins Sidney Kimmel Baltimore MD. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + DNMT1 viral mimicry mechanism absent + ERV/LINE demethylation absent + oral extended-duration AML maintenance pharmacology absent [10 pts]; FIRST oral azacitidine ever (134th mechanism class) + first AML maintenance HMA + QUAZAR AML-001 OS HR 0.69 [5 pts]; BMS Princeton NJ + Olon Rodano Italy + Johns Hopkins Baltimore MD [3 pts]; FIRST oral HMA for AML; FIRST drug approved for AML maintenance after intensive chemotherapy CR; FIRST OS benefit demonstrated for AML maintenance therapy [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_oral_azacitidine(cas: str, reading_ugm3: float) -> dict:
    """Scan oral CC-486 azacitidine with AML maintenance and viral mimicry context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "320-67-2"
                "reading_ugm3": reading_ugm3,
                "context": "oral_azacitidine_134th_class_first_ever_aml_maintenance_hma_viral_mimicry_erv_dnmt1_quazar"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, oral_formulation_flag, aml_maintenance_flag,
    #                    viral_mimicry_flag, dnmt1_extended_inhibition, h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_oral_azacitidine("320-67-2", 0.0024))
    print(r)
    # {'hd_category': 1, 'oral_formulation_flag': True, 'aml_maintenance_flag': True,
    #  'viral_mimicry_flag': True, 'dnmt1_extended_inhibition': True,
    #  'h350_h361_absent': True}